Apimeds Pharmaceuticals US, Inc (APUS)
Apimeds Pharmaceuticals US, Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in Matawan, NJ, US. The stock last traded at $4.28, down 7.56% on the session, giving a market capitalisation of $6.5M. On trailing twelve-month figures it carries a trailing P/E of -0.07, a net margin of 0.0%. Its beta of 0.15 implies it has historically moved less than the broad market.
Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.
Apimeds Pharmaceuticals US, Inc is most often compared with the following Healthcare names: